Abstract library

108 results for "pituitary hyperplasia-adenoma sequence".
#89 Hyperplasia-adenoma sequence in pituitary carcinogenesis: new insight into the role of AIP gene
Introduction: Pituitary adenoma predisposition has been recently associated with germline mutations in the Aryl-Hydrocarbon Receptor Interacting Protein (AIP) gene. This association has been detected in familial and, more rarely, in sporadic cases. The mechanisms by which the AIP mutations promote pituitary adenoma development remain unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Chiara Villa
#930 Distinct Expression of Splicing Variants of the Human MEN1 (Multiple Endocrine Neoplasia Type 1) Gene in Various Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant tumor syndrome characterized by the occurrence of tumors in multiple endocrine tissues, including parathyroid, enteropancreatic neuroendocrine and anterior pituitary. The MEN1 gene consists of 10 exons transcribed into a 610 a.a. protein. It was reported that heterogeneity of human MEN1 gene transcripts related to variation in their 5’ UTR. Six distinct exsons1 (e1A-e1F) were isolated using RNA from thymus, pancreas and kidney.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Atsushi Ozawa
Keywords: MEN1, pituitary
#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Antongiulio Faggiano
#2227 Screening Benefits in MEN1-Associated Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant syndrome characterized by tumors of the parathyroid glands (95%), endocrine pancreatic-gastroenteric tract (40%), and pituitary gland (30%).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: md Sabrina Chiloiro
#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes
Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect.
The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Erica Gentilin
#1206 Two Cases of Ectopic ACTH-Secreting Neoplasm of Occult Origin Becoming Overt After Bilateral Adrenalectomy
Introduction: Cushing's syndrome (CS) is an endocrine disorder associated with serious consequences if not adequately treated. Nearly 80% of the cases of endogenous hypercortisolism are adrenocorticotropic hormone (ACTH) dependent, the ACTH source being pituitary in about 70-80% and ectopic in 10-15%. The ACTH source may remain occult in few cases for many years in spite of extensive investigations.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Donato Iacovazzo
#2006 The Frequency of Patients with Giant Pituitary Tumors from Retrospective Data
Introduction: In this scientific article an author discusses the results of researches 121 patients with different by volume formations of sellar area, from them - men - 59 (48,9%), women - 62 (51,1%).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Professor Yulduz Urmanova
#1480 Systemic Treatment Sequences across Europe for Patients (pts) with Advanced Non-functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WD pNETs)
Introduction: Different systemic therapies (ST) are available for pts with advanced WD pNETs; however, the best treatment modalities and optimal sequencing are currently unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD PhD Ana Custodio
#111 Atypical lung carcinoid tumor metastatic to endocrine glands and bone marrow
Introduction: Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise 20% of all lung cancers. Typical low grade carcinoid tumors (TC) represent the majority of BP-carcinoids. Intermediate grade atypical carcinoid tumors (AC) are less often encountered but more aggressive. Although metastatic dissemination to mediastinal lymph nodes, liver, skeleton and central nervous system (CNS) is common, involvement of the endocrine glands has rarely been reported.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki